These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

556 related articles for article (PubMed ID: 29157392)

  • 41. The neuropathology of multiple sclerosis.
    Ludwin SK
    Neuroimaging Clin N Am; 2000 Nov; 10(4):625-48 ,vii. PubMed ID: 11359716
    [TBL] [Abstract][Full Text] [Related]  

  • 42. GD1a Overcomes Inhibition of Myelination by Fibronectin via Activation of Protein Kinase A: Implications for Multiple Sclerosis.
    Qin J; Sikkema AH; van der Bij K; de Jonge JC; Klappe K; Nies V; Jonker JW; Kok JW; Hoekstra D; Baron W
    J Neurosci; 2017 Oct; 37(41):9925-9938. PubMed ID: 28899916
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Axon loss in multiple sclerosis.
    Scolding N; Franklin R
    Lancet; 1998 Aug; 352(9125):340-1. PubMed ID: 9717917
    [No Abstract]   [Full Text] [Related]  

  • 44. Pathogenesis of axonal and neuronal damage in multiple sclerosis.
    Dutta R; Trapp BD
    Neurology; 2007 May; 68(22 Suppl 3):S22-31; discussion S43-54. PubMed ID: 17548565
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Remyelination therapies: a new direction and challenge in multiple sclerosis.
    Plemel JR; Liu WQ; Yong VW
    Nat Rev Drug Discov; 2017 Sep; 16(9):617-634. PubMed ID: 28685761
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cells of the oligodendroglial lineage, myelination, and remyelination.
    Miron VE; Kuhlmann T; Antel JP
    Biochim Biophys Acta; 2011 Feb; 1812(2):184-93. PubMed ID: 20887785
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Diverse targets for intervention during inflammatory and neurodegenerative phases of multiple sclerosis.
    Zamvil SS; Steinman L
    Neuron; 2003 Jun; 38(5):685-8. PubMed ID: 12797954
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Myelin repair stimulated by CNS-selective thyroid hormone action.
    Hartley MD; Banerji T; Tagge IJ; Kirkemo LL; Chaudhary P; Calkins E; Galipeau D; Shokat MD; DeBell MJ; Van Leuven S; Miller H; Marracci G; Pocius E; Banerji T; Ferrara SJ; Meinig JM; Emery B; Bourdette D; Scanlan TS
    JCI Insight; 2019 Apr; 4(8):. PubMed ID: 30996143
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Molecular "negativity" may underlie multiple sclerosis: role of the myelin basic protein family in the pathogenesis of MS.
    Musse AA; Harauz G
    Int Rev Neurobiol; 2007; 79():149-72. PubMed ID: 17531841
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The contribution of demyelination to axonal loss in multiple sclerosis.
    DeLuca GC; Williams K; Evangelou N; Ebers GC; Esiri MM
    Brain; 2006 Jun; 129(Pt 6):1507-16. PubMed ID: 16597651
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Demyelination in multiple sclerosis.
    Lubetzki C; Stankoff B
    Handb Clin Neurol; 2014; 122():89-99. PubMed ID: 24507514
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The road to remyelination in demyelinating diseases: current status and prospects for clinical treatment.
    Wootla B; Watzlawik JO; Denic A; Rodriguez M
    Expert Rev Clin Immunol; 2013 Jun; 9(6):535-49. PubMed ID: 23730884
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A new focal EAE model of cortical demyelination: multiple sclerosis-like lesions with rapid resolution of inflammation and extensive remyelination.
    Merkler D; Ernsting T; Kerschensteiner M; Brück W; Stadelmann C
    Brain; 2006 Aug; 129(Pt 8):1972-83. PubMed ID: 16714315
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Remyelination in multiple sclerosis.
    Piaton G; Williams A; Seilhean D; Lubetzki C
    Prog Brain Res; 2009; 175():453-64. PubMed ID: 19660673
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The pathology of multiple sclerosis and its evolution.
    Lassmann H
    Philos Trans R Soc Lond B Biol Sci; 1999 Oct; 354(1390):1635-40. PubMed ID: 10603616
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunologic aspects of multiple sclerosis.
    Boppana S; Huang H; Ito K; Dhib-Jalbut S
    Mt Sinai J Med; 2011; 78(2):207-20. PubMed ID: 21425265
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Differentiation and quantification of inflammation, demyelination and axon injury or loss in multiple sclerosis.
    Wang Y; Sun P; Wang Q; Trinkaus K; Schmidt RE; Naismith RT; Cross AH; Song SK
    Brain; 2015 May; 138(Pt 5):1223-38. PubMed ID: 25724201
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Quantifying visual pathway axonal and myelin loss in multiple sclerosis and neuromyelitis optica.
    Manogaran P; Vavasour IM; Lange AP; Zhao Y; McMullen K; Rauscher A; Carruthers R; Li DKB; Traboulsee AL; Kolind SH
    Neuroimage Clin; 2016; 11():743-750. PubMed ID: 27330974
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Review: Mitochondria and disease progression in multiple sclerosis.
    Mahad D; Lassmann H; Turnbull D
    Neuropathol Appl Neurobiol; 2008 Dec; 34(6):577-89. PubMed ID: 19076696
    [TBL] [Abstract][Full Text] [Related]  

  • 60. White matter involvement after TBI: Clues to axon and myelin repair capacity.
    Armstrong RC; Mierzwa AJ; Marion CM; Sullivan GM
    Exp Neurol; 2016 Jan; 275 Pt 3():328-333. PubMed ID: 25697845
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.